$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024035400 Filed on August 07, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue	$62.18M	$14.64M	$0.00
YoY Change
Cost Of Revenue	$2.152M	$636.0K
YoY Change
Gross Profit	$60.02M	$14.00M
YoY Change
Gross Profit Margin	96.54%	95.66%
Selling, General & Admin	$107.6M	$105.4M	$46.54M
YoY Change	289.8%	490.91%	219.68%
% of Gross Profit	179.24%	753.09%
Research & Development	$68.74M	$71.09M	$70.64M
YoY Change	-3.11%	3.62%	-0.14%
% of Gross Profit	114.53%	507.72%
Depreciation & Amortization	$298.0K	$267.0K	$142.0K
YoY Change	112.86%	111.9%	10.08%
% of Gross Profit	0.5%	1.91%
Operating Expenses	$178.5M	$177.2M	$117.2M
YoY Change	81.13%	104.95%	37.37%
Operating Profit	-$116.3M	-$162.5M	-$117.2M
YoY Change	18.03%	88.01%	37.37%
Interest Expense	$3.679M	$3.656M	$3.971M
YoY Change	4.99%	26.03%	136.09%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	-$107.0M	-$152.0M	-$112.2M
YoY Change	8.37%	77.12%	30.6%
Income Tax
% Of Pretax Income
Net Earnings	-$107.0M	-$152.0M	-$112.2M
YoY Change	8.33%	77.12%	30.6%
Net Earnings / Revenue	-172.04%	-1038.2%
Basic Earnings Per Share	-$4.92	-$7.10	-$5.68
Diluted Earnings Per Share	-$4.92	-$7.10	-$5.68
COMMON SHARES
Basic Shares Outstanding	21.71M shares	21.31M shares	19.74M
Diluted Shares Outstanding	21.75M shares	21.40M shares	19.76M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$998.6M	$1.058B	$634.1M
YoY Change	329.79%	254.47%	76.75%
Cash & Equivalents	$232.7M	$494.6M	$99.92M
Short-Term Investments	$765.9M	$563.2M	$534.2M
Other Short-Term Assets			$3.150M
YoY Change			21.39%
Inventory	$8.715M	$7.072M	$0.00
Prepaid Expenses
Receivables	$30.46M	$6.899M	$0.00
Other Receivables
Total Short-Term Assets	$1.064B	$1.092B	$637.3M
YoY Change	351.72%	261.98%	76.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.268M	$1.695M	$1.553M
YoY Change	244.16%	272.53%	158.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$9.599M	$8.061M	$3.266M
YoY Change	284.73%	830.83%	171.49%
TOTAL ASSETS
Total Short-Term Assets	$1.064B	$1.092B	$637.3M
Total Long-Term Assets	$9.599M	$8.061M	$3.266M
Total Assets	$1.073B	$1.100B	$640.5M
YoY Change	351.02%	263.61%	76.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$45.97M	$8.994M	$28.04M
YoY Change	177.87%	-48.71%	17.67%
Accrued Expenses	$131.0M	$115.6M	$89.98M
YoY Change	58.58%	41.4%	-1.62%
Deferred Revenue
YoY Change
Short-Term Debt			$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$177.8M	$125.2M	$118.5M
YoY Change	78.44%	25.53%	2.29%
LONG-TERM LIABILITIES
Long-Term Debt	$117.1M	$116.6M	$115.5M
YoY Change	2.06%	17.49%	134.29%
Other Long-Term Liabilities			$1.186M
YoY Change
Total Long-Term Liabilities	$118.3M	$117.5M	$116.7M
YoY Change	1.91%	18.4%	136.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$177.8M	$125.2M	$118.5M
Total Long-Term Liabilities	$118.3M	$117.5M	$116.7M
Total Liabilities	$296.1M	$242.7M	$235.2M
YoY Change	37.27%	21.97%	42.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.743B	-$1.636B	-$1.336B
YoY Change	42.37%	45.4%	38.81%
Common Stock	$2.519B	$2.493B	$1.741B
YoY Change	102.08%	102.88%	50.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$777.2M	$857.1M	$405.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.073B	$1.100B	$640.5M
YoY Change	351.02%	263.61%	76.67%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q4
OPERATING ACTIVITIES
Net Income	-$107.0M	-$152.0M	-$112.2M
YoY Change	8.33%	77.12%	30.6%
Depreciation, Depletion And Amortization	$298.0K	$267.0K	$142.0K
YoY Change	112.86%	111.9%	10.08%
Cash From Operating Activities	-$66.98M	-$134.9M	-$79.93M
YoY Change	-21.12%	79.19%	36.6%
INVESTING ACTIVITIES
Capital Expenditures	$779.0K	$5.131M	$1.036M
YoY Change	129.12%	7336.23%	3472.41%
Acquisitions
YoY Change
Other Investing Activities	-$201.6M	-$117.0M	-$361.1M
YoY Change	-498.92%	3093.2%	-643.67%
Cash From Investing Activities	-$202.4M	-$122.1M	-$362.1M
YoY Change	-503.17%	3171.65%	-645.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.462M	134.1M	479.9M
YoY Change	-61.89%	212.42%	81.55%
NET CHANGE
Cash From Operating Activities	-66.98M	-134.9M	-79.93M
Cash From Investing Activities	-202.4M	-122.1M	-362.1M
Cash From Financing Activities	7.462M	134.1M	479.9M
Net Change In Cash	-261.9M	-122.9M	37.86M
YoY Change	1629.94%	240.39%	-86.09%
FREE CASH FLOW
Cash From Operating Activities	-$66.98M	-$134.9M	-$79.93M
Capital Expenditures	$779.0K	$5.131M	$1.036M
Free Cash Flow	-$67.76M	-$140.1M	-$80.97M
YoY Change	-20.52%	85.83%	38.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	987000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11813000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	25631000	usd
	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-11258000	usd
	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-3562000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-284102000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-159377000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	290696000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2369797	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2369797	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21700893	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21700893	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.47
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18310952	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18310952	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18249778	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18249778	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	197389000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	11250000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-54000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	544000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	150136000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21754000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	10973000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	195000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-85800000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	103506000	usd
	us-gaap	Profit Loss ProfitLoss	-299512000	usd
	us-gaap	Profit Loss ProfitLoss	-162696000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	44306000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	22223000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	435000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	250000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1127000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6899000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	582000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7072000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-19047000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-6297000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9700000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	364988000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	346431000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	100204000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	488000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24045000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-190596000	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	50000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	288000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	707829000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95620000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	399682000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-254353000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99915000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	331549000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	499597000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77196000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.02
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	mdgl	Deferred Tax Assets Percentage Of Valuation Allowance DeferredTaxAssetsPercentageOfValuationAllowance	1
	us-gaap	Net Income Loss NetIncomeLoss	-299500000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1635800000	usd
CY2024Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	574000000	usd
CY2024Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	85900000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	5000000.0	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	499597000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	499597000	usd
CY2024Q2	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	1063162000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	373000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1062794000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	633663000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	476000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	634131000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5728000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1344000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	7072000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q2	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	65473000	usd
CY2023Q4	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	50737000	usd
CY2024Q2	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	4206000	usd
CY2023Q4	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	3724000	usd
CY2024Q2	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	2045000	usd
CY2023Q4	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	9705000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21341000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17030000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	15496000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6814000	usd
CY2024Q2	mdgl	Accrued Expenses Gross AccruedExpensesGross	1931000	usd
CY2023Q4	mdgl	Accrued Expenses Gross AccruedExpensesGross	0	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5119000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1970000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	115611000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14899	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	600000	usd
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	900000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	6400000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	12768000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	79604000	usd
CY2024Q2	mdgl	Long Term Debt Maturity After Year Two LongTermDebtMaturityAfterYearTwo	53387000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	152159000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	31007000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4545000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	116607000	usd
	mdgl	Common Stock Voting Rights Number CommonStockVotingRightsNumber	1	vote
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2355779	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	79.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	148970	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	232.88
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	671947	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	73.91
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	59995	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	118.98
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1772807	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	93.76
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1323994	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	79.14
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24404000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10973000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44306000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22223000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24404000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10973000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44306000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22223000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	149100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M2D
	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1600000	usd
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-035400-index-headers.html	Edgar Link	pending
0001628280-24-035400-index.html	Edgar Link	pending
0001628280-24-035400.txt	Edgar Link	pending
0001628280-24-035400-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mdgl-20240630.htm	Edgar Link	pending
mdgl-20240630.xsd	Edgar Link	pending
mdgl-20240630xex311.htm	Edgar Link	pending
mdgl-20240630xex312.htm	Edgar Link	pending
mdgl-20240630xex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mdgl-20240630_cal.xml	Edgar Link	unprocessable
mdgl-20240630_def.xml	Edgar Link	unprocessable
mdgl-20240630_lab.xml	Edgar Link	unprocessable
mdgl-20240630_pre.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mdgl-20240630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2024 Q3 Form 10-Q Financial Statement

#000162828024035400 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2024 Q3 Form 10-Q Financial Statement

#000162828024035400 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl